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The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft 
Survival: Insights into Reno-Cardiac Interactions. Olga Laur, Meredith A. Brisco, and 
Jeffrey M. Testani. Section of Cardiology, Department of Internal Medicine, Yale University, 
School of Medicine, New Haven, CT 
Background: Renal dysfunction (RD) is a potent risk factor for death in patients with 
cardiovascular disease. This relationship may be causal since experimentally induced RD 
produces findings such as myocardial necrosis and apoptosis in animals. Cardiac transplantation 
provides an opportunity to investigate this hypothesis in humans; if direct myocardial damage is 
principally responsible for the substantial risk associated with RD, this risk should be transferable 
from a donor with RD to the recipient via the allograft. 
Methods: Cardiac transplantations from the UNOS registry were studied (n=23,056). RD was 
defined as an estimated glomerular filtration rate < 60 ml/min/1.73m.2 
Results: RD was present in 17.9% of donors and 39.4% of recipients. Donor characteristics that 
could theoretically result in myocardial damage such as longer ischemic time, older age, diabetes, 
hypertension, and cigarette use were associated with increased graft failure (p≤0.007 for all). 
However, donor RD was not associated with graft failure (age-adjusted HR=1.00, 95% CI 0.94-
1.07, p=0.92). Moreover, in recipients with RD the highest risk for graft failure occurred 
immediately post-transplant (0-30 day HR=1.8, 95% CI 1.54-2.02, p<0.001) with subsequent 
attenuation of the risk over time (30-365 day HR=0.92, 95% CI 0.77-1.09, p=0.33). 
Conclusions: The risk associated with RD does not appear to be transferrable from donor to 
recipient via the cardiac allograft and the risk associated with recipient RD is greatest 
immediately following transplant.  These observations suggest that the non-myocardial aspects of 
cardio-renal dysfunction are of particular importance in the risk associated with RD.
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Renal dysfunction (RD) is common in patients with cardiovascular disease and is 
strongly associated with increased morbidity and mortality.1-7 Notably, this association 
persists after extensive adjustment for potential confounders, such as diabetes or 
hypertension, raising the possibility of a causal relationship. One potential mechanism by 
which RD may directly worsen outcomes is via direct myocardial damage.8-12 Support for 
this possibility is derived from animal studies where experimentally induced RD results 
in pathology such as necrosis, apoptosis, fibrosis, arteriolar thickening, decreased 
capillary density, and contractile dysfunction.13-19 Remarkably, some of these findings 
have also been reported following only brief exposures to RD in the setting of 
experimental acute kidney injury (AKI).20  
Whether RD can cause direct myocardial damage in humans with enough severity 
to influence outcomes is unknown and represents a difficult hypothesis to test. In addition 
to potential direct myocardial effects, the epidemiologic signal for adverse outcomes 
associated with RD could also be driven by non-myocardial/peripheral factors intrinsic to 
the RD milieu, which are difficult to measure. These factors could take the shape of 
systemic myocardial depressant factors (i.e., “uremic toxins”) effects on the vasculature 
and other organs, in addition to unmeasured confounding factors (i.e., underutilization of 
beneficial therapies due to the RD or unmeasured disease severity).   
Cardiac transplantation provides an opportunity to begin to investigate the 
importance of myocardial vs. peripheral effects of RD since the heart is being 
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transplanted into and out of the RD environment. When a heart is removed from a donor 
with RD, the peripheral RD environment will remain with the donor.  However, any RD-
induced myocardial damage will travel to the recipient with the graft. Thus, if significant 
myocardial damage occurs with RD we would expect this injury to travel with the heart 
and result in reduced post-transplant graft survival in recipients (Figure 1).21 In essence, 
this finding would be similar to the concept that the myocardial damage induced by 
factors such a longer graft ischemic time or from advanced donor age results in worsened 




Figure 1. Hypothetical effect of donor RD on graft survival in recipients under 
assumption that donor RD causes direct myocardial damage  
 
 Similarly, transplanting a healthy heart into a recipient with RD would be 
expected to result in a progressive increase in risk over time after enough myocardial 
damage accumulates from the RD to begin to impact clinical outcomes(Figure 2).  




Figure 2. Hypothetical effect of recipient RD on graft survival in recipients under 
assumption that RD causes myocardial damage which accumulates in a time-
dependent manner   
 
However, if the risk associated with RD is primarily driven by the host’s 
peripheral RD environment (i.e., systemic myocardial depressant factors), we would 
expect to see limited risk from donor RD but a significant up-front risk associated with 
transplant of a healthy donor heart into the environment of recipient RD. That is, we 
would expect the rate of graft failure to be accelerated post-transplantation in a group of 
recipients with RD followed by stabilization in the rate of graft failure between the two 
groups following a critical period of time (Figure 3).  




Hypothetical effect of recipient RD graft survival in recipients under assumption 
that RD is a marker of patient disease severity rather then causes direct myocardial 
damage 
Study aim:  
As such, the primary purpose of this analysis was to evaluate the risk associated 
with donor RD on post-transplant outcomes and to determine the temporal pattern of 
cardiovascular risk associated with recipient RD following transplantation of healthy 
donor hearts. This was accomplished using heart transplant records from United Network 
for Organ Sharing (UNOS) database, which is a national database that collects recipient 
and donor heart transplant data via established questionnaires distributed to all of the 
transplant centers. 
 
Hypothesis 1: It is unlikely that renal dysfunction exerts direct damaging effect on 
myocardium and thus transplantation of donor hearts with and without history of RD will 
yield similar recipient graft outcomes. 




Hypothesis 2: It is unlikely that renal dysfunction exerts direct damaging effect on 
myocardium and thus transplantation of donor hearts with and without history of 
proteinuria will yield similar recipient graft outcomes.  
 
Hypothesis 3: It is unlikely that renal dysfunction exerts direct damaging effect on 
myocardium and thus transplantation of donor heart into the recipient environment of RD 
will not result in a time-dependent acceleration in graft failure compared to donor graft 
transplantation into recipients with no history of RD. Instead, we would expect to see a 
significant up-front risk associated with transplant of a healthy donor heart into the 
environment of recipient RD. 
Methods: 
Patient Population: 
 Cardiac transplant donor and recipient data were obtained for adult cardiac 
transplants between January 2000 and March 2013 (N=28,513) from the United Network 
for Organ Sharing (UNOS) database. Patients receiving either heart-lung or heart-kidney 
transplants and those with missing data on donor and recipient serum creatinine, donor 
race, or graft outcomes were excluded. For patients who underwent re-transplantation 
(n=1,620), only data on the first transplant was retained. Overall, 23,056 patients met the 
inclusion criteria (Figure 4). 




Figure 4. Consort diagram 
 
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.22 Terminal creatinine 
was used for donor eGFR calculation; serum creatinine at the time of transplant was used 
for recipient eGFR calculation. Subsequent recipient renal function was evaluated in a 
subset of patients with follow-up data available (n = 8,802). RD was defined as an eGFR 
< 60 ml/min/1.73m2.23, 24 Both donor and recipient groups were additionally stratified 
into National Kidney Foundation (NKF) stages of CKD severity (GFR ≥ 90 
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ml/min/1.73m2, GFR 60-89 ml/min/1.73m2, GFR 30-59 ml/min/1.73m2, and GFR <30 
ml/min/1.73m2 where NKF stages 4 and 5 were combined).23 Several donor or recipient 
dichotomous characteristics had a high degree of missingness (i.e., recipient cigarette use 
missing >30%) and there was prognostic information associated with the missing state of 
these variables. To ensure that the multivariable models captured as much risk as possible, 
these variables were coded using three levels (i.e., cigarette use yes, no, missing).  
 
Statistical Analysis: 
The primary focus of this analysis was (1) the association between donor RD and 
cardiac graft failure and (2) the time-dependent nature of the association between 
recipient RD and cardiac graft failure. A secondary analysis focused on the relationship 
between donor proteinuria and cardiac allograft failure. The primary endpoint of these 
analyses was recipient graft failure which was defined as retransplantation or recipient 
death during the study period. Values reported are mean ± SD or median (quartile 1 – 
quartile 4) for continuous variables, or percentile for categorical variables.  Independent 
Student’s t test was used to compare continuous variables. The Pearson chi-square test 
was used to evaluate associations between categorical variables. Correlation coefficients 
reported are Spearman’s rho.  
  Cox proportional hazards models were used to evaluate time-to-event 
associations between both donor RD and recipient RD with graft failure. Patients were 
censored if lost to follow-up or alive at the conclusion of the data collection period 
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(March 2013). Given the strong influence of donor age on graft survival and the strong 
influence of age on calculated eGFR, all models evaluating the association between 
eGFR and graft failure were adjusted for age unless otherwise specified.21, 25 Covariates 
for multivariable models included all donor, recipient and graft-related factors with a 
univariate association with graft failure at p<0.2 or a theoretical basis for confounding 
(donor and graft covariates = gender, diabetes, hypertension, cigarette use, cause of death, 
CMV status, infection, inotrope use, ischemic time, and donor ejection fraction; recipient 
covariates = eGFR, age, gender, race, BMI, diabetes, hypertension, cerebrovascular 
disease, ischemic cardiomyopathy, cigarette use, UNOS status at listing, mechanical 
ventilation, inotrope, intra-aortic balloon pump, mechanical circulatory support use, 
recipient CMV status, and donor-recipient mismatch in gender). Kaplan-Meier survival 
curves were plotted for four groups of donor and recipient eGFR (eGFR ≥ 90, eGFR 60-
89, eGFR 30-59, and eGFR <30 ml/min/1.73m2).  The x-axis was terminated when the 
number at risk was <10% and statistical significance was determined using the log-rank 
test. When evaluating the association between recipient eGFR and graft failure, our 
primary focus was how the effect of RD on graft outcomes changed over time. As such, 
we performed an extended adjusted cox model utilizing two Heaviside functions to 
examine the magnitude of the effect of RD on graft outcomes in the first 30 days and 
from 30 days to 1 year.  For all analyses, a p-value of <0.05 was considered statistically 
significant. Statistical analyses were performed using SPSS Version 19 (IBM SPSS 
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Statistics, IBM Corporation, Armonk, New York) and Stata 13.0 (Statacorp, College 
Station Texas). 
Coding analysis: 
All coding necessary for UNOS database cleaning, donor and recipient eGFR estimation, 
univariate and multivariate cox regression analysis for donor RD, donor proteinuria, and 
recipient RD over the total length of the post-transplant follow-up was performed by me 
using SPSS software (see below). Adjusted extended cox model utilizing two Heaviside 
function was performed by Dr. Meredith Brisco via Stata software.  
 
Coding for estimation of eGFR in donor and recipient: 
**CKD EPI equation  race 1 = African American ; 0 = non African American** 
Compute EPIsexMultiplier=$sysmis. 
if Race_don eq 1 and gender_don eq "F" EPIsexMultiplier=166. 
if Race_don eq 1 and gender_don eq "M" EPIsexMultiplier=163. 
if Race_don eq 0 and gender_don eq "F" EPIsexMultiplier=144. 




if  gender_don eq "F" and creat_don LE 0.7 EPIexponent=-0.329. 
if  gender_don eq "F" and creat_don gt 0.7 EPIexponent=-1.209. 
if  gender_don eq "M" and creat_don LE 0.9 EPIexponent=-0.411. 
if  gender_don eq "M" and Creat_don gt 0.9 EPIexponent=-1.209. 






if gender_don="F" Episex= 0.7. 








Coding for stratifying donor and recipient groups into stages: 
COMPUTE CKD_EPI_donorstage=$sysmis. 
if CKD_EPI_donor ge 90 CKD_EPI_donorstage= 0. 
if CKD_EPI_donor ge 60 and CKD_EPI_donor lt 90 CKD_EPI_donorstage=1. 
if CKD_EPI_donor ge 30 and CKD_EPI_donor lt 60 CKD_EPI_donorstage=2. 





if CKD_EPI_recip ge 90 CKD_EPI_recipstage= 0. 
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if CKD_EPI_recip ge 60 and CKD_EPI_recip lt 90 CKD_EPI_recipstage=1. 
if CKD_EPI_recip ge 30 and CKD_EPI_recip lt 60 CKD_EPI_recipstage=2. 
if CKD_EPI_recip ge 0 and CKD_EPI_recip lt 30 CKD_EPI_recipstage=3. 
EXECUTE. 
 
Coding for unadjusted donor RD cox regression model: 
 
COXREG time  
  /STATUS=gfailure(1)  
  /METHOD=ENTER CKD_EPI60donor age_doncox10  
  /PRINT=CI(95)  
  /CRITERIA=PIN(.05) POUT(.10) ITERATE(20). 
 
Coding for unadjusted donor proteinuria cox regression model: 
 
COXREG time  
  /STATUS=gfailure(1)  
  /METHOD=ENTER prot_donor  
  /PRINT=CI(95)  
  /CRITERIA=PIN(.05) POUT(.10) ITERATE(20). 
 
Coding for donor RD cox regression model adjusted with donor and recipient risk 
factors:  
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    COXREG time  
      /STATUS=gfailure(1)  
      /CONTRAST (htn_recip1)=Indicator(1)  
     /CONTRAST (cig_recip1)=Indicator(1) 
   /CONTRAST (cmv_recip1)=Indicator(1) 
 /CONTRAST (allinotropes1)=Indicator(1) 
    /METHOD=ENTER  CKD_epi60donor CKD_epirecipcox10 agecox10 gender_recip 
gender_mismatch1 race_recip BMI_CALC  diab_recip htn_recip1  cereb_recip  
cig_recip1  
 ischCM  vent_recip inotropes_trr iabp_trr stat_recip ischtime LV_eject cmv_recip1 
mech_circ_support  age_doncox10 gender_donor diab_donor htn_donor cig_donor   
 cod_anoxia_donor  cmv_donor donor_infection allinotropes1  
    /PRINT=CI(95)  
      /PRINT=CI(95) 
      /CRITERIA=PIN(.05) POUT(.20) ITERATE(20). 
 
Coding for donor proteinuria cox regression model adjusted with donor and recipient risk 
factors: 
    COXREG time  
      /STATUS=gfailure(1)  
       /CONTRAST (htn_recip1)=Indicator(1)  
     /CONTRAST (cig_recip1)=Indicator(1) 
   /CONTRAST (cmv_recip1)=Indicator(1) 
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 /CONTRAST (allinotropes1)=Indicator(1) 
    /METHOD=ENTER  prot_donor CKD_epirecipcox10 agecox10 gender_recip 
gender_mismatch1 race_recip BMI_CALC  diab_recip htn_recip1  cereb_recip  
cig_recip1  
 ischCM  vent_recip inotropes_trr iabp_trr stat_recip ischtime LV_eject cmv_recip1 
mech_circ_support  age_doncox10 gender_donor diab_donor htn_donor cig_donor   
 cod_anoxia_donor  cmv_donor donor_infection allinotropes1   
    /PRINT=CI(95)  
      /PRINT=CI(95) 
      /CRITERIA=PIN(.05) POUT(.20) ITERATE(20). 
 
 
Coding for recipient RD unadjusted Cox regression model: 
 
COXREG time  
  /STATUS=gfailure(1)  
  /METHOD=ENTER CKD_EPI60recip agecox10  
  /PRINT=CI(95)  
  /CRITERIA=PIN(.05) POUT(.10) ITERATE(20). 
 
Coding for recipient RD cox regression model adjusted with donor and recipient risk 
factors: 
    COXREG time  
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      /STATUS=gfailure(1)  
      /CONTRAST (htn_recip1)=Indicator(1)  
     /CONTRAST (cig_recip1)=Indicator(1) 
   /CONTRAST (cmv_recip1)=Indicator(1) 
 /CONTRAST (allinotropes1)=Indicator(1) 
    /METHOD=ENTER  CKD_epi60recip CKD_epi_donorcox10 agecox10 gender_recip 
gender_mismatch1 race_recip BMI_CALC  diab_recip htn_recip1  cereb_recip  
cig_recip1  
 ischCM  vent_recip inotropes_trr iabp_trr stat_recip ischtime LV_eject cmv_recip1 
mech_circ_support  age_doncox10 gender_donor diab_donor htn_donor cig_donor   
 cod_anoxia_donor  cmv_donor donor_infection allinotropes1  
    /PRINT=CI(95)  
      /PRINT=CI(95) 
      /CRITERIA=PIN(.05) POUT(.20) ITERATE(20). 
 
Coding provided by Dr. Meredith Brisco: 
**FINAL MODEL evaluating Hazard ratio associated with recipient RD at 1 month post-
transplantation and following 1 month post transplantation.  
 
stsplit rd, at(30) 
gen rd1mo=CKD_EPI60recip*(rd==30) 
 
xi: stcox CKD_EPI60recip rd1mo age_doncox10 




xi: stcox CKD_EPI60recip rd1mo age_doncox10  CKD_EPI_donorcox10 agecox10 
gender_recip gender_mismatch1 race_recip BMI_CALC /// 
diab_recip i.htn_recip1 cereb_recip i.cig_recip1 ischCM vent_recip INOTROPES_TRR 
IABP_TRR stat_recip ischtime LV_EJECT i.cmv_recip1 ///  
mech_circ_support gender_donor diab_donor htn_donor cig_donor  cod_anoxia_donor 




In total, 23,056 patients met the inclusion criteria. Baseline donor characteristics 
stratified by presence of donor RD are presented in Table 1. 





Donor RD Present P-value 
Characteristic 
(n = 23,056) No (n = 18,919) Yes (n = 4,137) 
 
Demographics 
    
 
Age, years  31.6 ± 12.2 30.9 ± 12.1 34.6 ± 11.9 <0.001 
 Age > 50 years 8.0% 7.5% 10.3% <0.001 
 
Female gender  28.6% 28.3% 30.1% 0.020 
 
White race 85.9% 86.4% 83.5% <0.001 
 
BMI 26.6 ± 5.6 26.3 ± 5.5 28.1 ± 5.9 <0.001 




   
 
 Diabetes mellitus 2.6% 2.3% 4.2% <0.001 
 
Hypertension 13.1% 11.2% 21.5% <0.001 
 
Cigarette use  22.6% 22.3% 23.8% 0.030 
 
Alcohol use 19.5% 19.0% 22.2% 0.013 
 
CMV positive  61.3% 61.2% 61.8% 0.460 
 Suspected infection 7.0%  6.9% 7.6% 0.094 
Donor cause of death    
 
 
Anoxia  13.3% 10.8% 
25.1% <0.001 
 Stroke 24.9% 24.2% 
28.0% <0.001 
 Head trauma 60.8% 63.9% 
46.5% <0.001 
Cardiac allograft     
 Ischemic time, hours  
3.2 ± 1.0 3.2 ± 1.0 3.2±1.0 0.013 
 
Ischemic time ≥ 4 hours 21.0% 20.8% 22.2% 0.050 
 
LVEF, % 61.6 ± 7.6 61.5 ± 7.7 61.8 ± 7.6 0.047 
 
LVEF ≤ 45% 2.2% 2.3% 1.9% 0.100 
 
Inotropic support 61.9% 61.6% 63.3% 0.045 
Laboratory values    
 
 BUN, mg/dl 15.5  ± 12.4 12.7 ± 7.8 28.0 ± 19.7 <0.001 
 
Creatinine, mg/dl 1.3 ± 1.2 0.9 ± 0.3 2.8 ± 2.1 <0.001 
 
eGFR, ml/min/1.73m2 92.2 ± 34.8 104.1 ± 25.0 37.7 ± 16.3 <0.001 
 Proteinuria 32.6% 28.8% 50.1% <0.001 




RD: renal dysfunction, BMI: body mass index, CMV: cytomegalovirus, LVEF: left 




 RD was present in 17.9% of donors with a mean eGFR that was significantly depressed 
at 37.7 ± 16.3 ml/min/1.73m2 and an elevated creatinine at 2.8 ± 2.1 mg/dl. Donors with 
RD were older, with a substantially higher prevalence of diabetes, hypertension, and 
death from anoxic cause. However, measures of cardiac allograft function such as 
ejection fraction and inotrope use were generally similar between groups as was the graft 
ischemic time (Table 1). 
Donor RD and graft failure: 
Out of 23,056 recipients, 6,852 (29.7%) experienced graft failure during a median 
follow-up of 3.9 (IQR 1.1-7.0) years. Serving as a positive control, donor risk factors 
that could potentially induce myocardial damage such as older donor age, hypertension, 
diabetes, cigarette use, and longer ischemic time were all significantly associated with 
recipient graft failure (Figure 5 and Table 2).  
Table 2. Donor and recipient characteristics and their associations with graft failure 
 HR 95% CI P-value 
Donor Characteristics    
Age, per 10 year increase 1.11 1.09-1.14 <0.001 
Age > 50 years 1.35 1.25-1.46 <0.001 
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Female gender 1.12 1.07-1.18 <0.001 
Diabetes mellitus 1.22 1.05-1.41 0.007 
Hypertension 1.13 1.06-1.22 <0.001 
Cigarette use  1.18 1.11-1.24 <0.001 
CMV positive  1.11 1.06-1.16 <0.001 
Suspected infection (blood) 1.12 1.02-1.22 0.02 
Donor inotropic support 1.07 1.01-1.13 0.02 
Donor cause of death: anoxia 1.02 0.95-1.10 0.56 
Donor renal function *    
eGFR, per 10 ml/min/1.73m2  increase 1.00 0.99-1.01 0.96 
eGFR < 90 ml/min/1.73m2 1.02 0.97-1.07 0.44 
eGFR < 60 ml/min/1.73m2 1.00 0.94-1.07 0.92 
eGFR < 45 ml/min/1.73m2 1.00 0.93-1.09 0.96 
eGFR < 30 ml/min/1.73m2 0.92 0.83-1.03 0.14 
Creatinine, per 1mg/dl increase 1.00 0.97-1.02 0.65 
Creatinine > 1.5 mg/dl 1.01 0.95-1.08 0.71 
Creatinine > 2.0 mg/dl 0.94 0.86-1.04 0.22 
Creatinine > 2.5 mg/dl 0.99 0.89-1.10 0.78 
Proteinuria  1.00 0.95-1.05 0.96 
Cardiac Allograft Characteristics    
Ischemic time, hours  1.08 1.05-1.10 <0.001 
Ischemic time ≥ 4 hours 1.22 1.15-1.29 <0.001 
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LVEF, % 1.00 1.00-1.00 0.62 
LVEF ≤ 45% 1.12 0.96-1.29 0.15 
Recipient Characteristics    
Age, per 10 year increase 1.00 0.98-1.02 0.76 
Female gender  1.06 1.00-1.12 0.04 
Gender mismatch  1.15 1.08-1.22 <0.001 
Race  1.35 1.27-1.44 <0.001 
BMI 1.01 1.00-1.02 <0.001 
Diabetes mellitus  1.19 1.13-1.26 <0.001 
Hypertension 1.17 1.11-1.24 <0.001 
Cerebrovascular disease  1.18 1.07-1.30 0.001 
Cigarette use 1.09 1.02-1.17 0.01 
Ischemic cardiomyopathy  1.16 1.10-1.21 <0.001 
CMV positive 1.10 1.04-1.16 <0.001 
Inotropic support 1.05 1.00-1.10 0.07 
IABP  1.22 1.10-1.34 <0.001 
Mechanical circulatory support  1.14 1.07-1.22 <0.001 
UNOS status 1A  1.13 1.08-1.19 <0.001 
Mechanical ventilation  1.20 1.04-1.37 0.01 
Recipient renal function *    
Recipient eGFR, per 10 
ml/min/1.73m2 increase 
0.95 0.94-0.96 <0.001 
Recipient eGFR < 90 ml/min/1.73m2 1.13 1.06-1.21 <0.001 
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Recipient eGFR < 60 ml/min/1.73m2 1.28 1.21-1.34 <0.001 
Recipient eGFR < 45 ml/min/1.73m2 1.45 1.37-1.54 <0.001 
Recipient eGFR < 30 ml/min/1.73m2 1.80 1.60-1.94 <0.001 
 
*All donor eGFR covariates were adjusted for donor age and recipient eGFR covariates 
were adjusted for recipient age.  CMV: cytomegalovirus, eGFR: estimated glomerular 
filtration rate, LVEF: left ventricular ejection fraction, RD: renal dysfunction, BMI: body 




Figure 5. Risk of graft failure from selected donor risk factors with theoretical 
direct deleterious effects on the myocardium. eGFR: estimated glomerular filtration 
rate. *Due to the dependence of eGFR on age, all eGFR categories were adjusted for 
donor age.   
 
However, there was no significant relationship between donor RD and graft 
failure (HR=1.05 95% CI 0.98-1.12 p=0.14).  Following adjustment for age, the hazard 
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ratio further approached unity (HR= 1.00, 95% CI 0.94-1.07, p=0.92).  A similar lack of 
association between donor RD and graft failure was observed with larger reductions in 
eGFR and using creatinine-based cut points to define RD (Figure 5). Further adjustment 
for other donor characteristics (HR=0.99, 95% CI 0.92-1.06, p=0.76) or donor and 
recipient characteristics did not alter the lack of relationship between donor RD and graft 
survival (HR= 0.98, 95% CI 0.92-1.05, p=0.60, Table 3).  
 Table 3. Association between donor renal dysfunction and recipient graft failure 
adjusted for donor and recipient risk factors 
 HR 95% CI P-value 
Donor Characteristics    
eGFR < 60 ml/min/1.73m2 0.98 0.92-1.05 0.60 
Age, per 10 year increase 1.11 1.08-1.13 <0.001 
Female gender 0.96 0.86-1.07 0.45 
Diabetes mellitus 1.18 1.01-1.38 0.04 
Hypertension 0.95 0.88-1.04 0.26 
Cigarette use 1.07 1.00-1.14 0.03 
CMV positive 1.1 1.05-1.17 <0.001 
Suspected infection (blood) 1.10 1.00-1.22 0.06 
Cause of death: anoxia 1.07 0.99-1.17 0.10 
Inotropic support* 1.04 0.97-1.1 0.26 
Cardiac Allograft Characteristics    
Ischemic time, hours 1.07 1.04-1.10 <0.001 
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LVEF, % 1.00 1.00-1.00 0.19 
Recipient Characteristics    
Age (per 10 year increment) 0.93 0.90-0.95 <0.001 
Female gender 1.14 1.05-1.24 0.003 
Gender mismatch 1.18 1.04-1.33 0.01 
Black race 1.40 1.31-1.50 <0.001 
BMI 1.00 1.00-1.01 0.34 
Diabetes mellitus 1.14 1.07-1.21 <0.001 
Hypertension* 1.12 1.05-1.20 <0.001 
Cerebrovascular disease 1.10 0.98-1.22 0.11 
Cigarette use* 1.05 0.98-1.14 0.19 
Ischemic cardiomyopathy 1.19 1.13-1.27 <0.001 
CMV positive* 1.04 0.98-1.10 0.21 
Inotrope use 1.02 0.96-1.07 0.59 
IABP 1.08 0.97-1.22 0.17 
Mechanical circulatory support 1.20 1.11-1.30 <0.001 
UNOS status 1A 1.11 1.05-1.18 <0.001 
Mechanical ventilation 1.19 1.02-1.38 0.03 
eGFR, per 10 ml/min/1.73m2 increase 0.95 0.94-0.96 <0.001 
 
*Missing data in these covariates was coded as a separate category due to its prevalence 
(9% for donor inotropic support; 50% for recipient hypertension; 36% for recipient 
history of cigarette use, 6% for recipient cmv positive status).  The associated HR 
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specifically represents the risk of graft failure in a group with one of these risk factors vs. 
without.  eGFR: estimated glomerular filtration rate, CMV: cytomegalovirus, LVEF: left 
ventricular ejection fraction, RD: renal dysfunction, BMI: body mass Index, IABP: intra-
aortic balloon pump, UNOS: United Network of Organ Sharing. 
 
A “dose-response” relationship between donor eGFR and graft failure was not 
apparent as progressively worse donor CKD stages (Figure 6) and eGFR as a continuous 
parameter (adjusted HR=1.00 per 10 ml/min/1.73m2, 95% CI 1.00-1.01, p=0.37) were 
not associated with increased risk of graft failure.
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Figure 6. Kaplan-Meier survival plots stratified by donor eGFR categories. eGFR: 
estimated glomerular filtration rate in mL/min/1.73m2.  
 
Donor proteinuria and graft failure: 
 In total, 32.6% of donors (n=7,406) had proteinuria at the time of evaluation. Not 
surprisingly, proteinuria was more common in donors with hypertension (37.1% vs. 
31.9%, p<0.001) and in donors with diabetes (41.2% vs. 32.3%, p<0.001). Donor 
proteinuria was not associated with decreased graft survival (HR=1.00, 95% CI 0.95-1.05, 
p=0.96, Figure 5), and this lack of association persisted with extensive adjustment for 
donor and recipient characteristics (HR=1.00, 95% CI 0.94-1.06, p=0.97, Figure 7). 





Figure 7. Kaplan-Meier survival plots stratified by donor proteinuria.  
Recipient characteristics: 
Baseline characteristics of recipients with and without RD are presented in Table 
4. 
 
Table 4. Baseline recipient characteristics stratified by presence or absence of 
recipient renal dysfunction 
 Overall 
Cohort 
Recipient RD present P - value 
Characteristic (n = 23,056) No (n = 13,982) Yes (n = 9,074)  
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Demographics     
 Age, years 52.3 ± 12.3 49.3 ± 13.0 56.8 ± 9.7 <0.001 
 Female gender 24.4% 24.2% 24.7% 0.372 
 Gender mismatch  15.8% 16.3% 15.1% 0.017 
 White race  82.7% 80.9% 85.6% <0.001 
 BMI 26.8 ± 4.8 26.5 ± 4.9 27.2 ± 4.6 <0.001 
Comorbidities     
 Diabetes mellitus  24.0% 21.0% 28.6% <0.001 
 Hypertension  40.1% 38.2% 42.9% <0.001 
 Peripheral vascular 
disease  
3.4% 2.7% 4.5% <0.001 
 Cerebrovascular disease  5.5% 5.2% 6.0% 0.011 
 Cigarette use  49.0% 48.1% 50.5% 0.005 
 Ischemic cardiomyopathy  38.4% 35.2% 43.4% <0.001 
 CMV positive 62.1% 61.1% 63.6% <0.001 
Disease severity at 
transplant 
    
 I otropes  43.0% 41.0% 45.9% <0.001 
 IABP  5.3% 5.1% 5.7% 0.028 
 Mechanical circulatory 
support  
21.8% 24.1% 18.2% <0.001 
 UNOS status 1A  44.2% 45.6% 42.1% <0.001 
 Mechanical ventilation  4.1% 4.3% 3.9% 0.093 
Cardiac allograft     
 Ischemic time (hours) 3.2 ± 1.0 3.2 ±1.0 3.2 ±1.0 0.110 
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 Ischemic time ≥ 4 hours  21.0% 20.7% 21.5% 0.137 
 LVEF 61.6 ± 7.6 61.7±7.6 61.4±7.7 0.008 
 LVEF ≤ 45% 2.2% 2.0% 2.5% 0.010 
Laboratory values     
 Creatinine, mg/dl 1.3 ± 0.7 1.0 ± 0.2 1.8 ± 0.8 <0.001 
 eGFR, ml/min/1.73m2 69.9 ± 26.5 86.2 ± 20.1 44.7 ± 10.9 <0.001 
Hemodynamics     
 MPAP, mm/Hg 28.3 ± 10.2 27.9 ± 10.3 29.0 ± 10.0 <0.001 
 PCWP, mm/Hg 18.8 ± 8.8 18.5 ± 8.9 19.2 ± 8.6 <0.001 
 TPG, mm/Hg 9.6 ± 5.4 9.5 ± 5.5 9.8 ± 5.3  0.001 
 CO, L/min 4.5 ± 1.5 4.5 ±1.5 4.6 ±1.5 0.018 
 PVR, Wood units  2.4 ±2.0 2.4 ± 1.9 2.4 ± 2.0 0.324 
 
RD: renal dysfunction, BMI: body mass Index, CMV: cytomegalovirus, IABP: intraaortic 
balloon pump, UNOS: United Network of Organ Sharing, LVEF: left ventricular ejection 
fraction, eGFR: estimated glomerular filtration rate, MPAP: mean pulmonary arterial 
pressure, PCWP: pulmonary capillary wedge pressure, TPG: transpulmonary gradient, 
CO: cardiac output, PVR: pulmonary vascular resistance. 
 
 The mean eGFR of the population was 69.9 ± 26.5 ml/min/1.73m2 and RD was 
present in 39.4% of recipients.  Amongst recipients with RD, the mean eGFR was 44.7 ± 
10.9 ml/min/1.73m2.  Similar to donors, recipients with RD were older and more likely to 
have evidence of CVD in the form of ischemic cardiomyopathy and peripheral vascular 
disease. Additionally, recipients with RD exhibited several indices of increased HF-
   
 
28 
disease severity including greater utilization of inotropes and intra-aortic balloon pumps 
and higher filling pressures. Pre-transplant allograft function was similar between 
recipients with and without RD. When only those recipients who received allografts from 
RD-free donors were examined (n=18,919), the observed similarities and differences 
between those recipients with and without RD were similar (data not shown). 
Recipient RD and timing of graft failure: 
Over the entire follow-up period, recipient RD was significantly associated with 
poor graft outcomes even following extensive adjustment for donor and recipient 
characteristics (Adjusted HR=1.27, 95% CI 1.20-1.34, p<0.001). However, there was a 
significant difference in the risk attributable to RD which varied over time (p time-
dependent interaction = <0.001).  Interestingly, the highest risk of graft failure associated 
with RD occurred immediately within the first 30 days post-transplant (adjusted HR=1.76, 
95% CI 1.54-2.02, p<0.001). The risk associated with RD subsequently decreased as 
time went on such that the hazard associated with baseline RD from 30 days to 1 year no 
longer significantly impacted subsequent graft survival (HR=0.92, 95% CI 0.77-1.09, 
p=0.33, Table 5, Figure 8).  
Table 5. Association between recipient renal dysfunction and recipient graft failure 
adjusted for donor and recipient risk factors 
 HR 95% CI P-value 
Recipient Characteristics    
eGFR < 60 ml/min/1.73m2, within 1st 
month  
1.76 1.54-2.02 <0.001 
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eGFR < 60 ml/min/1.73m2, 1 month to 1 
year  
0.92 0.77-1.09 0.33 
Age, per 10 year increase 0.94 0.92-0.97 <0.007 
Female gender 1.14 1.05-1.24 <0.001 
Gender mismatch 1.17 1.03-1.33 0.015 
Black race 1.39 1.30-1.49 <0.001 
BMI 1.00 1.00-1.01 0.23 
Diabetes mellitus 1.13 1.06-1.21 <0.001 
Hypertension* 1.14 1.06-1.21 <0.001 
Cerebrovascular disease 1.10 0.98-1.22 0.10 
Cigarette use* 1.06 0.98-1.14 0.16 
Ischemic cardiomyopathy 1.19 1.12-1.26 <0.001 
CMV positive* 1.03 0.97-1.09 0.30 
Inotrope use 1.03 0.97-1.09 0.31 
IABP 1.06 0.94-1.20 <0.31 
Mechanical circulatory support 1.16 1.07-1.27 <0.001 
UNOS status 1A 1.12 1.05-1.18 <0.001 
Mechanical ventilation 1.20 1.03-1.39 0.021 
Cardiac Allograft Characteristics    
Ischemic time, hours 1.06 1.04-1.09 <0.001 
LVEF, % 1.00 1.00-1.00 0.12 
Donor Characteristics    
Age, per 10 year increase 1.11 1.08-1.14 <0.001 
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Female gender 0.96 0.86-1.07 0.43 
Diabetes mellitus 1.15 0.97-1.35 0.11 
Hypertension 0.96 0.88-1.04 0.31 
Cigarette use 1.08 1.01-1.14 0.02 
CMV positive 1.11 1.05-1.17 <0.001 
Suspected infection (blood) 1.10 1.00-1.22 0.06 
Cause of death: anoxia 1.08 0.99-1.18 0.08 
Inotropic support* 1.04 0.98-1.11 0.23 
eGFR, per 10 ml/min/1.73m2 increase 1.00 1.00-1.01 0.39 
 
*Missing data in these covariates was coded as a separate category due to its prevalence 
(9% for donor inotropic support; 50% for recipient hypertension; 36% for recipient 
history of cigarette use, 6% for recipient cmv positive status).  The associated HR 
specifically represents the risk of graft failure in a group with one of these risk factors vs. 
without. eGFR: estimated glomerular filtration rate, CMV: cytomegalovirus, LVEF: left 
ventricular ejection fraction, RD: renal dysfunction, BMI: body mass Index, IABP: intra-
aortic balloon pump, UNOS: United Network of Organ Sharing. 
 
 





Figure 8. Kaplan-Meier survival curves stratified by recipient eGFR categories. eGFR: 
estimated glomerular filtration rate in mL/min/1.73m2. 
The attenuation in risk did not appear to be primarily driven by recovery in renal 
function; when patients with data on repeat renal function were evaluated (data available 
37%, median time to follow-up creatinine = 6.0 years), eGFR in patients with RD did not 
meaningfully improve post-transplant (baseline eGFR 45.0 ± 10.5 ml/min/1.73m2 vs. 
follow-up eGFR 47.3 ± 20.1 ml/min/1.73m2). Similar findings of an early period of high 
risk followed by attenuation in risk was observed when examining only cardiac allografts 
from donors without RD (p interaction = 0.13).  




Principal Findings of the Study: 
 
The principal findings of this study are 1) RD in a cardiac donor, regardless of its 
severity, is not associated with worsened graft survival and 2) the risk of graft failure 
associated with recipient RD is substantial and most pronounced in the first 30 days 
following cardiac transplantation with subsequent attenuation in the risk over time. Thus 
RD-associated risk cannot be transferred between patients via the myocardium, but 
placement of a healthy myocardium into a host with RD results in immediate worsening 
in outcomes. The pattern of this risk is most consistent with the concept that the primary 
source of risk associated with RD is derived from the peripheral or non-myocardial 
aspects of the cardio-renal environment.   
A large body of evidence from animal models has clearly demonstrated that 
significant adverse myocardial structural changes such as apoptosis, necrosis, and 
fibrosis occur with experimentally induced RD.13-20 Given that these are known 
mediators of disease in humans, it is reasonable to believe if the above pathology also 
occurred in humans with RD it would result in worse outcomes. Importantly, despite 
significant pathologic changes, animal systolic function was only mildly or not impaired 
at all, suggesting that if this damage occurred in humans it would likely not be avoided 
during the allograft screening process.16 Consistent with the above premises, it has 
previously been reported that factors which plausibly can cause direct myocardial 
damage such as older donor age, hypertension, and diabetes have been linked to 
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worsened post-transplant graft survival. These findings serve as “positive controls” that 
subclinical myocardial damage in the donor can be transmitted to the recipient despite the 
donor screening process.21, 26-30 However, even with severe RD in the donor the risk 
associated with donor RD approached zero in a sample size of >23,000 patients. 
Although the graft selection process and complicated peri-transplant management of 
these patients may have attenuated the signals in this study, the complete lack of a 
detectable risk with donor RD argues that the peripheral RD environment is the dominant 
factor in RD-associated risk.  
 Further support for the above concept is provided by the findings with respect to 
recipient RD.  Importantly, substantial acute systolic dysfunction has not been a 
predominant finding in animal models of experimentally induced RD and we could not 
detect any signal for worsened outcomes with donor RD, which was likely acute in the 
majority of cases.16 As a result even if myocardial damage began to occur immediately 
following transplant of a healthy donor heart into a recipient with RD, myocardial 
dysfunction would not be expected to manifest itself in immediately worsened outcomes.  
Rather, only over months to years as myocardial damage accumulated would we expect 
to see worsened outcomes associated with recipient RD if the myocardial pathology was 
the dominant driver. To the contrary, we found that when donor hearts were placed into 
the environment of recipient RD the opposite pattern was apparent with substantially 
increased risk immediately following transplant, followed by attenuation of the risk over 
time. Unlike a delayed effect as myocardial injury accumulates from RD, the peripheral 
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aspects of RD such as unmeasured disease severity, underutilization of beneficial 
therapies (i.e, calcineurin inhibitors), and systemic myocardial depressant factors would 
be expected to be the most pronounced immediately after transplant.  The finding of a 
substantially increased early risk associated with RD followed by subsequent attenuation 
is in line with the latter hypothesis.  
The direct implication of this study is that transplantation of appropriately 
selected hearts from donors with even significant RD does not appear to worsen post-
transplant outcomes.  However, this analysis also may shed some light on potential 
therapeutic approaches toward cardio-renal dysfunction.  If transplantation of a heart 
from a donor with RD was associated with worse post-transplant outcomes, this would 
indicate that once cardio-renal syndrome occurs, the damage is likely irreversible.  
However, the absence of a risk associated with donor RD and attenuation of the risk 
associated with recipient RD over time post-transplant suggests that the risk associated 
with cardio-renal dysfunction may be modifiable.  Further research is necessary to better 
understand the non-myocardial determinants of RD associated risk and evaluate if 
strategies to improve these risk factors could improve outcomes in these patients.   
 
Study Limitations: 
This study is subject to limitations inherent to analyses of a retrospective post-hoc 
study, such as uncontrolled confounding and reliance on data from a large registry. It is 
unclear to what degree transplantation and subsequent treatment with nephrotoxic 
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medications such as calcineurin inhibitors may have influenced the RD-graft survival 
association. Furthermore, although RD is not a standard parameter that is considered in 
the organ selection process, we do not have data on how RD may have affected the organ 
refusal rate. Post-transplant decisions such as the choice of immunosuppression may 
have been influenced by recipient RD, potentially altering the post-transplant graft failure 
risk. Additionally, the graft failure outcome was primarily driven by recipient death, 
which could represent non-myocardial events such as infection or malignancy. Although 
renal function did not appear to improve post-transplant in the patients with serial 
creatinine values available, long-term changes in renal function were not available in the 
majority of patients, and when this data was available it was several years after the 
transplant.  As a result, in some patients improvement in renal function may have 
occurred attenuating the risk associated with time of transplant RD at later time periods.    
In conclusion, the risk associated with RD does not appear to be transferrable 
from donor to recipient via the cardiac allograft and the risk associated with recipient RD 
is greatest immediately following transplant.  Overall these data support the safety of 
transplantation of appropriately selected allografts from donors with RD.  Additionally, 
these data suggest that the non-myocardial aspects of cardio-renal dysfunction appear to 
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Supplementary materials:  
 
Abstract accepted at Amereican College of Cardiology conference 2014: 
Donor and Recipient Renal Dysfunction and Post Cardiac Transplant Graft 
Survival - Insights Into Cardiorenal Interactions 
Authors: Olga Laur, Meredith Brisco, Alexander Kula, Susan Cheng, Steve Coca, Abeel 
Mangi, Wilson Tang, Jeffrey Testani 
 
Background: The major mode of death in patients with renal dysfunction (RD) is 
cardiovascular disease (CVD). Notably, there may be a causal effect of RD given that 
myocardial necrosis/apoptosis has been seen in animal models of RD. However, RD is 
also a marker of overall CVD severity. Cardiac transplantation provides an opportunity to 
study this as hearts are being transplanted in and out of the environment of RD: If 
irreversible myocardial damage occurs immediately with RD, as seen in animal models 
of acute kidney injury, transplantation of a heart from a donor with RD should yield 
reduced graft survival. However, if cardiac damage from RD develops gradually, 
transplantation of a healthy RD-free donor heart into a recipient with RD should yield an 
initial low risk period followed by high event rates months to years later. 
Methods: Adult cardiac allograft recipients in the UNOS registry were studied 
(n=35,914). RD was defined as estimated glomerular filtration rate (eGFR) < 60 
ml/min/1.73m2. 
Results: RD was present in 17.2 % of donors and 39.4% of recipients with an overall 
worsening in eGFR over time in recipients (p<0.001). Donor characteristics known to 
cause or reflect myocardial damage such as ischemic time > 4 hours (adjusted HR 1.2, 
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p<0.001), age > 50 years (adjusted HR=1.3, p<0.001), or ejection fraction ≤ 45% 
(adjusted HR 1.2, p=0.03) were associated with reduced graft survival. To the contrary, 
the risk associated with RD did not follow the heart as transplantation from a donor with 
RD did not reduce graft survival (adjusted HR=0.98, p=0.44).  RD-free donor hearts 
placed into a recipient with RD paradoxically had the highest risk of graft dysfunction in 
the first 30 post-operative days (Adjusted HR 1.6, p<0.001). Subsequently, the hazard 
attributable to recipient RD (adjusted HR 1.2, p<0.001) did not increase over time 
(p=0.8) as would be expected with slow accumulation of myocardial damage from RD. 
Conclusion: Transplantation of a heart in and out of the environment of RD was not 
associated with worsened outcomes in a manner consistent with a clinically meaningful 
direct effect of RD on the myocardium. These data provide additional support that RD 
primarily serves as a marker rather than a direct cause of CVD. 
 
Abstract accepted at International Society for Heart and Lung transplantation conference 
in April 2014: 
 
Donor and Recipient Renal Dysfunction and Post Cardiac Transplant Graft 
Survival - Insights Into Reno-Cardiac Interactions 
Authors: Olga Laur, Meredith Brisco, Alexander Kula, Susan Cheng, Steve Coca, Abeel 
Mangi, Wilson Tang, Jeffrey Testani 
 
Background: The major mode of death in patients with renal dysfunction (RD) is 
cardiovascular disease (CVD). Notably, there may be a causal effect of RD given that 
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myocardial necrosis/apoptosis has been seen in animal models of RD. However, RD is 
also a marker of overall CVD severity. Cardiac transplantation provides an opportunity to 
study this as hearts are being transplanted in and out of the environment of RD: If 
irreversible myocardial damage occurs immediately with RD, as seen in animal models 
of acute kidney injury, transplantation of a heart from a donor with RD should yield 
reduced graft survival. However, if cardiac damage from RD develops gradually, 
transplantation of a healthy RD-free donor heart into a recipient with RD should yield an 
initial low risk period followed by high event rates months to years later. 
Methods: Adult cardiac allograft recipients in the UNOS registry were studied 
(n=35,914). RD was defined as estimated glomerular filtration rate (eGFR) < 60 
ml/min/1.73m2. 
Results: RD was present in 17.2 % of donors and 39.4% of recipients with an overall 
worsening in eGFR over time in recipients (p<0.001). Donor characteristics known to 
cause or reflect myocardial damage such as ischemic time > 4 hours (adjusted HR 1.2, 
p<0.001), age > 50 years (adjusted HR=1.3, p<0.001), or ejection fraction ≤ 45% 
(adjusted HR 1.2, p=0.03) were associated with reduced graft survival. To the contrary, 
the risk associated with RD did not follow the heart as transplantation from a donor with 
RD did not reduce graft survival (adjusted HR=0.98, p=0.44).  RD-free donor hearts 
placed into a recipient with RD paradoxically had the highest risk of graft dysfunction in 
the first 30 post-operative days (Adjusted HR 1.6, p<0.001). Subsequently, the hazard 
attributable to recipient RD (adjusted HR 1.2, p<0.001) did not increase over time 
(p=0.8) as would be expected with slow accumulation of myocardial damage from RD. 
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Conclusion: Transplantation of a heart in and out of the environment of RD was not 
associated with worsened outcomes in a manner consistent with a clinically meaningful 
direct effect of RD on the myocardium. These data provide additional support that RD 
primarily serves as a marker rather than a direct cause of CVD. 
 
 
 
